{
    "ticker": "OCUL",
    "name": "Ocular Therapeutix, Inc.",
    "description": "Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for eye care. Founded in 2013, Ocular is dedicated to addressing significant unmet medical needs in the field of ophthalmology through its proprietary drug delivery platform technology. The company's lead product, Dextenza, is a sustained-release dexamethasone insert designed for the treatment of post-surgical ocular inflammation and pain. Dextenza is designed to deliver medication directly to the eye for an extended period, enhancing patient adherence and improving outcomes. Ocular is also advancing its pipeline of product candidates targeting conditions such as glaucoma, dry eye disease, and retinal diseases. The company's mission is to transform the treatment of eye diseases and improve the quality of life for patients by providing innovative, effective, and user-friendly solutions. Ocular Therapeutix is committed to leveraging its expertise in drug formulation and delivery to develop products that can change the landscape of ophthalmic care.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Bedford, Massachusetts, USA",
    "founded": "2013",
    "website": "https://www.oculotherapeutix.com",
    "ceo": "Anthony DiMarco",
    "social_media": {
        "twitter": "https://twitter.com/OcularThera",
        "linkedin": "https://www.linkedin.com/company/ocular-therapeutix/"
    },
    "investor_relations": "https://ir.oculotherapeutix.com",
    "key_executives": [
        {
            "name": "Anthony DiMarco",
            "position": "CEO"
        },
        {
            "name": "David W. Miller",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Therapeutics",
            "products": [
                "Dextenza",
                "Ocular Therapeutix Pipeline Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ocular Therapeutix, Inc. | Innovative Ophthalmic Therapies",
        "meta_description": "Discover Ocular Therapeutix, Inc., a leader in ophthalmic drug delivery solutions. Learn about our innovative products and commitment to improving eye care.",
        "keywords": [
            "Ocular Therapeutix",
            "Ophthalmology",
            "Dextenza",
            "Eye Care",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Ocular Therapeutix do?",
            "answer": "Ocular Therapeutix develops innovative therapies for ophthalmic conditions using advanced drug delivery technology."
        },
        {
            "question": "What is Dextenza?",
            "answer": "Dextenza is a sustained-release dexamethasone insert used for treating post-surgical ocular inflammation and pain."
        },
        {
            "question": "Where is Ocular Therapeutix headquartered?",
            "answer": "Ocular Therapeutix is headquartered in Bedford, Massachusetts, USA."
        },
        {
            "question": "When was Ocular Therapeutix founded?",
            "answer": "Ocular Therapeutix was founded in 2013."
        }
    ],
    "competitors": [
        "AVEO",
        "RETA",
        "OCGN"
    ],
    "related_stocks": [
        "AAPL",
        "AMGN",
        "GILD",
        "PFE"
    ]
}